Researchers Say Treat the Risk, Not the Cholesterol
January 22, 2010 - A new study by the University of Michigan Medical School and VA Ann Arbor Health System challenges the medical thinking that the lower the cholesterol, the better. Instead, they suggest tailoring treatment to a patient's overall heart attack risk, by considering all their risk factors, such as age, family history, and smoking status.
Researchers said the approach of considering all factors was more effective and used fewer high-dose statins than current strategies to drive down cholesterol to a certain target.
While study authors support the use of cholesterol-lowering statins, they conclude that patients and their doctors should consider all the factors that put them at risk for heart attack and strokes. The findings will be released online Monday, Jan. 25, ahead of print in the Annals of Internal Medicine.
“We’ve been worrying too much about people’s cholesterol level and not enough about their overall risk of heart disease,” says Rodney A. Hayward, M.D., director of the Veterans Affairs Center for Health Services Research and Development and a professor of internal medicine at the University of Michigan Medical School.
The National Cholesterol Education Program recommends harmful LDL cholesterol levels should be less than 130 for most people. High-risk patients should be pushed even lower, to less than 70.
The U-M study took a different approach, called tailored treatment, which uses a person's risk factors and mathematical models to calculate the expected benefit of treatment, by considering:
• A person's risk of a heart attack or stroke without treatment
• How much a statin decreases the risk
• Potential harms from the treatment
“These are the three factors that determine the net benefit of a treatment. Our fixation on just one factor, LDL cholesterol, is leading us to often treat the wrong people,” Dr. Hayward said.
In the recent study, U-M physicians who worked with Yale University School of Medicine used data from statin trials that included Americans ages 30-75 with no history of heart attack.
Study authors evaluated the benefit of five years of treatment that was tailored, on coronary artery disease risk factors such as age, family history, diabetes, high blood pressure, smoking status, and recently CRP, C-reactive protein.
The tailored approach was more efficient (more benefit per person treated) and prevented substantially more heart attacks, strokes and cardiovascular deaths than the currently recommended treat-to-target approaches. The tailored strategy treated fewer individuals with high-dose statins and saved 500,000 more quality-adjusted life years.
“The bottom line message – knowing your overall heart attack risk is more important than knowing your cholesterol level,” Dr. Hayward said. “If your overall risk is elevated, you should probably be on a statin regardless of what your cholesterol is and if your risk is very high, should probably be on a high-dose of statin.”
“However, if your LDL cholesterol is high, but your overall cardiac risk is low, taking a statin does not make sense for you,” Dr. Hayward explained. “If your cholesterol is your only risk factor and you're younger, you should work on diet and exercise.”
Research has increasingly emerged questioning the value of cholesterol targets and which of statins mechanisms is most important to preventing cardiac events. Cholesterol-lowering drugs work by blocking a key enzyme linked with LDL cholesterol production, but they initiate other changes in the body.
“Statins also affect inflammation on the inside of our blood vessels, which is often what causes heart attacks and strokes – it’s not just a matter of cholesterol alone,” he says.
Additional authors were Harlan M. Krumholz, M.D., Yale University School of Medicine, and Donna M. Zulman, M.D., Justin W. Timbie, Ph.D., and Sandeep Vijan, M.D, all of the VA Center for Health Services Research and Development, VA Ann Arbor Health Care System.
Funding for the study came from the VA Health Services Research and Development Service's Quality Enhancement Research Initiative and the Measurement Core of the Michigan Diabetes Research and Training Center of the National Institutes of Health.
For more information: www.med.umich.edu/medschool, www.annarbor.hsrd.research.va.gov, www.annarbor.va.gov, www.nhlbi.nih.gov/about/ncep/index.htm
More like this
- FDA Approves First Generic Version of Cholesterol-Lowering Drug Lipitor
- Statin-Based Drug Lowers Bad Cholesterol
- Benefits of Statin Therapy May Extend Beyond Lowering Lipids
- Statin Gains New European Indication to Prevent Cardiovascular Events
- Study Finds Obese Kids' Artery Plaque Similar to Middle-Aged Adults